Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study will be conducted at Rigshospitalet in Copenhagen, Denmark, and will enroll up to 39 patients. Participants will be prospectively selected based on PTGR1 overexpression and DNA-damage-repair deficiency, reflecting the company's commitment to precision medicine.
The trial will evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies, addressing a significant unmet need in bladder cancer treatment. This clearance marks a critical step for Lantern Pharma as it further advances its AI-driven precision oncology strategy through its proprietary RADR platform. The company leverages artificial intelligence and machine learning to transform the development of cancer therapies, and this trial represents a key validation of that approach.
Bladder cancer is the tenth most common cancer worldwide, with limited treatment options for advanced stages. Standard therapies often have low response rates and significant side effects, underscoring the need for novel targeted treatments. LP-184 is designed to exploit DNA repair deficiencies in cancer cells, potentially offering a more effective and less toxic alternative. The biomarker selection criteria aim to identify patients most likely to benefit, increasing the trial's efficiency and the likelihood of success.
Lantern Pharma's pipeline includes other promising candidates, such as LP-284 for hematologic and solid tumors, and LP-300, which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. The company also recently commercialized withZeta.ai, a multi-agentic AI co-scientist platform, now available as a subscription-based research tool for the global biomedical community, representing a new revenue stream.
The EMA clearance is a significant milestone for Lantern Pharma, demonstrating regulatory progress and the potential of its AI-driven approach to bring new therapies to patients. The trial's initiation in Europe also expands the company's global footprint, with operations including an AI Center of Excellence in Bengaluru, India, and headquarters in Dallas, Texas. For more details, the full press release is available at https://ibn.fm/6ku4F. Further information about Lantern Pharma can be found at their newsroom: https://ibn.fm/LTRN.
